Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine

Cancer Research

Volumn 69, Issue 4, 2009, Pages 1494-1501

  Shnitsar, Volodymyr ^a   Eckardt, Ronny ^a   Gupta, Shivangi ^a   Grottker, Julia ^a   Müller, Gerhard A ^b   Koepsell, Hermann ^c   Burckhardt, Gerhard ^a   Hagos, Yohannes ^a,b  

^a Abteilung Vegetative Physiologie und Pathophysiologie   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 METHYL PYRIDINIUM IODIDE; IRINOTECAN; MELPHALAN; ORGANIC CATION TRANSPORTER 3; PYRIDINIUM DERIVATIVE; THYMIDINE; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ARTICLE; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG INHIBITION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; CHO CELLS; CRICETINAE; CRICETULUS; DNA PRIMERS; HUMANS; KIDNEY NEOPLASMS; MELPHALAN; ORGANIC CATION TRANSPORT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; VINCRISTINE;

EID: 60549103094     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2483     Document Type: Article

References (36)

1. Bakhiya N, Stephani M, Bahn A, et al. Uptake of chemically reactive, DNA-damaging sulfuric acid esters into renal cells by human organic anion transporters. J Am Soc Nephrol 2006;17:1414-21.
2. De Mulder PH, van Herpen CM, Mulders PA. Current treatment of renal cell carcinoma. Ann Oncol 2004;15 Suppl 4:iv319-28.
3. Arany I, Safirstein RL. Cisplatin nephrotoxicity. Semin Nephrol 2003;23:460-4.
4. Gillet JP, Efferth T, Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 2007;1775:237-62.
5. Perez-Tomas R. Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 2006;13:1859-76.
6. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006;234:4-33.
7. Burckhardt BC, Burckhardt G. Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol 2003;146: 95-158.
8. Wright SH, Dantzler WH. Molecular and cellular physiology of renal organic cation and anion transport. Physiol Rev 2004;84:987-1049.
9. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 2007;24: 1227-51.
10. Shibayama Y, Ushinohama K, Ikeda R, et al. Effect of methotrexate treatment on expression levels of multi-drug resistance protein 2, breast cancer resistance protein and organic anion transporters Oat1, Oat2 and Oat3in rats. Cancer Sci 2006;97:1260-6.
11. Ciarimboli G, Ludwig T, Lang D, et al. Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol 2005;167: 1477-84.
12. Zhang S, Lovejoy KS, Shima JE, et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 2006;66:8847-57.
13. Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3and multidrug and toxin extrusion family). J Pharmacol Exp Ther 2006;319:879-86.
14. Rao GN, Corson MA, Berk BC. Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 1991;266:8604-8.
15. van Montfoort JE, Hagenbuch B, Groothuis GM, Koepsell H, Meier PJ, Meijer DK. Drug uptake systems in liver and kidney. Curr Drug Metab 2003;4:185-211.
16. Anzai N, Kanai Y, Endou H. Organic anion transporter family: current knowledge. J Pharmacol Sci 2006;100: 411-26.
17. Rizwan AN, Burckhardt G. Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res 2007;24: 450-70.
18. Hayer-Zillgen M, Bruss M, Bonisch H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br JPharmacol 2002;136:829-36.
19. Shang T, Uihlein AV, Van Asten J, Kalyanaraman B, Hillard CJ. 1-Methyl-4-phenylpyridinium accumulates in cerebellar granule neurons via organic cation transporter 3. J Neurochem 2003;85:358-67.
20. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human ATP-binding cassette and solute carrier transporter superfamilies. Drug Metab Pharma-cokinet 2005;20:452-77.
21. Smith PC, Karpowich N, Millen L, et al. ATP binding to the motor domain from an ABC transporter drives formation of a nucleotide sandwich dimer. Mol Cell 2002;10:139-49.
22. Han B, Zhang JT. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2. Curr Med Chem Anticancer Agents 2004;4:31-42.
23. Suzuki T, Nishio K, Tanabe S. The MRP family and anticancer drug metabolism. Curr Drug Metab 2001;2: 367-77.
24. Rodriguez-Menendez V, Gilardini A, Bossi M, et al.
25. Valproate protective effects on cisplatin-induced peripheral neuropathy: an in vitro and in vivo study. Anticancer Res 2008;28:335-42.
26. Okabe M, Unno M, Harigae H, et al. Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun 2005; 333:754-62.
27. Sunters A, Springer CJ, Bagshawe KD, Souhami RL, Hartley JA. The cytotoxicity, DNA crosslinking ability and DNA sequence selectivity of the aniline mustards melphalan, chlorambucil and 4-[bis(2-chloroethyl)amino] benzoic acid. Biochem Pharmacol 1992;44:59-64.
28. Grachev MA, Mustaev AA, Oshevski SI. A route to RNA with an alkylating group at the 5′-triphosphate residue. Nucleic Acids Res 1980;8:3413-26.
29. Uchino H, Kanai Y, Kim DK, et al. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol Pharmacol 2002;61:729-37.
30. Shimada Y, Rothenberg M, Hilsenbeck SG, Burris HA III, Degen D, Von HoffDD. ActivityofCPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs 1994;5:202-6.
31. Stewart CF. Topoisomerase I interactive agents. Cancer Chemother BiolResponse Modif2001;19:85-128.
32. Toffoli G, Cecchin E, Corona G, Boiocchi M. Pharmacogenetics of irinotecan. Curr Med Chem Anticancer Agents 2003;3:225-37.
33. Fellous A, Ohayon R, Vacassin T, et al. Biochemical effects of Navelbine on tubulin and associated proteins. Semin Oncol 1989;16:9-14.
34. Islam MN, Iskander MN. Microtubulin binding sites as target for developing anticancer agents. Mini Rev Med Chem 2004;4:1077-104.
35. McClean S, Hosking LK, Hill BT. Expression of P-glycoprotein-mediated drug resistance in CHO cells surviving a single X-ray dose of 30 Gy. Int J Radiat Biol 1993;63:765-73.
36. McGuire SA, Gospe SM, Jr., Dahl G. Acute vincristine neurotoxicity in the presence of hereditary motor and sensory neuropathy type I. Med Pediatr Oncol 1989;17: 520-3.